Becton, Dickinson’s 2.1% Yield and 12.8x Forward P/E Signal 33% Upside to $255
BDX trades at $176.66 with forward P/E of 12.82 and yields 2.1%, reflecting a 33% discount to a $255 target at its 1.6% low-yield mark. ROIC of 10%, economic EPS of $6.45 and book value of $217.66 support a buy recommendation driven by dividend mispricing and recurring demand.
1. Valuation and Dividend Mispricing
At a share price of $176.66, Becton, Dickinson posts a forward P/E of 12.82 and a dividend yield of 2.1%, marking a 33% discount to a $255 valuation at a 1.6% low-yield threshold and up to 90% upside to $355 at a 1.1% high-yield threshold.
2. Fundamentals and Cash Flows
Key financial metrics include a return on invested capital of 10%, a 4% free cash flow yield, economic EPS of $6.45 surpassing GAAP EPS of $5.81, and an economic book value of $217.66 per share, all signaling sound profitability and balance sheet strength.
3. Business Segments and Recurring Demand
The company’s diversified portfolio spans five segments—Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences—anchored by recurring demand for IV catheters, medication delivery systems, pre-fillable solutions and advanced patient monitoring platforms across global healthcare markets.
4. Buy Recommendation
These valuation indicators, coupled with durable demand and robust cash flows, form the basis for a buy recommendation on Becton, Dickinson shares as market mispricing appears to understate the company’s intrinsic value and total return potential.